Biotechnology and Pharmaceuticals · australia
Putting Biologics into a Swallowable Capsule: Biora Cleared to Begin BioJet’s First Human Trial
BioJet will use liquid jets to deliver drugs into the small intestine, challenging biologics’ reliance on injections. An Australian ethics committee has cleared the study; a trial in healthy volunteers must now answer whether swallowed adalimumab can safely and consistently enter the bloodstream.
For patients who need long-term injections of biologics, a swallowable capsule could offer an alternative that may ease the burden of daily treatment. But swallowing a drug and getting enough of it into the bloodstream are two separate challenges. The BioJet capsule developed by Biora Therapeutics is preparing for its first test of this delivery process in humans.
Biora announced on November 4 that it had received approval from an Australian Human Research Ethics Committee (HREC) to begin BioJet’s first human trial. The study will compare the safety, tolerability, and pharmacokinetics of adalimumab delivered orally via the capsule with those of subcutaneous injection in healthy volunteers. The company expects dosing to begin in December 2026 and data to be available in early 2027; no human trial results have been announced yet.
At the core of BioJet is liquid jet technology designed to deliver biologics into small intestinal tissue after the capsule is swallowed, allowing the drugs to enter systemic circulation from there. It seeks to change how drugs pass through the intestine. According to the company’s description and reporting by BioPharm International, the device can use existing liquid biologic formulations without reformulation for oral delivery; whether this design can work reliably in humans remains to be confirmed in the trial.
Adalimumab, the drug selected for this study, is normally administered by injection. Comparing two delivery routes for the same drug helps researchers observe the extent to which the drug enters the bloodstream after capsule administration and how its concentration changes. However, a trial in healthy volunteers primarily addresses questions about early safety and drug exposure; it cannot directly demonstrate that this delivery method can maintain disease control in patients.
Before the human study, Biora said it had used more than 800 BioJet capsules in large-animal studies. This figure describes the number of capsules used, not the number of animals studied, and cannot be used to infer human safety. In addition to showing whether the drug can enter circulation, subsequent data will need to clarify differences in delivery between participants and the tolerability of the device’s operation within the intestine.
This ethics approval advances the company’s plan, announced in September, to begin a human study before the end of the year. At the time, Biora said trial data could support regulatory submissions for further clinical development in 2027; this remains dependent on the study results and subsequent review. Ethics committee clearance for the study also does not mean the device has been approved for marketing. BioJet remains an investigational product.
If early human data support its feasibility, BioJet will explore another delivery route for existing biologics. But moving from a single swallowed capsule to long-term treatment will require more evidence, including safety with repeated use, consistency of drug exposure, and treatment performance in actual patients. The upcoming study is the first human test along that path.